Rethinking Clinical Trials with Faster AI-Driven Decision Making
AI is revolutionizing drug development by enabling faster, evidence-based decisions across clinical trial phases. Novartis's Shefali Kakar explains how integrated modeling reduces costly late-stage failures and provides deeper understanding of patient-specific drug responses.
Rethinking Clinical Trials with Faster AI-Driven Decision Making
Report an error
The correction channel is not available yet. You can copy the article reference below for later.
Correction instructionsSummary only
Under the source content permission, this page provides an editorial summary, key points, and a link to the original article.